

02 August 2024

India | Equity Research | Q1FY25 results review

## Sun Pharmaceutical Industries

Pharma

### Swift growth in India aids an operationally in-line quarter

Sun Pharma's (Sun) Q1FY25 revenue and EBITDA was in line with expectations. Sun had increased its field force count by nearly 44% in the last four years and ~160 brands in Indian market in the last two years, which helped it grow at 16% in Q1, i.e., 1.8x of India pharma market's growth rate. Specialty biz is expected to get a boost from the launches of Nidlegly in Europe and Leqselvi (deuruxolitinib) in US (subject to outcome of litigation by Incyte Corp.) while existing products such as Ilumya (8% market share in US IL-23 market) and Winlevi are poised to boost specialty products sales (18% CAGR over FY24-26E). Management aims to grow its revenue in single-digit in FY25. We raise our FY25E/26E EPS by ~5-6%. Retain **HOLD**, TP revised to INR 1,635 (INR 1,463 earlier) based on 30x FY26E earnings (28x earlier).

### Revenue and EBITDA in-line; other income boost profits

Revenues grew 6% YoY (5.6% QoQ) to INR 126.5bn (I-Sec: INR 128bn), led by strong performance in India. Gross margins rose 200bps YoY (-130bps QoQ) to 78.9% due to improvement in product mix. EBITDA grew 8.3% YoY to INR 36.1bn (I-Sec: INR 35.6bn). EBITDA margins expanded 60bps YoY (+320bps QoQ) to 28.5% (I-Sec: 27.8%), marginally impacted by higher R&D and marketing costs. Adj. PAT grew of 24.1% YoY (+2.9% QoQ) to INR 28.4bn (I-Sec: INR 25.9bn) aided by higher other income (up 160.5% YoY).

### Levulan slows down specialty run-rate; India growth cheering

US revenue declined 2.1% QoQ (-1.1% YoY) to USD 466mn. Sun's generic business, excluding gRevlimid (flat QoQ), has grown on a sequential basis. Global specialty revenue declined 1.8% QoQ to USD 266mn due to lower sales of Levulan on account of seasonality, save for this, other products have grown QoQ. We expect overall US sales CAGR at 8.4% over FY24-26E to ~USD 2.2bn driven by a ramp-up in Ilumya and Winlevi. India business grew at 16.4% YoY driven by better volumes across therapies and new launches. Sun had launched six new products in Q1FY25. We expect domestic business CAGR of 9% over FY24-26E. EMs grew 10.5% YoY at INR 23.7bn. RoW region sales, at INR 15.8bn, declined 1.4% YoY impacted by price cuts in Japan. API sales declined 8.3% YoY to INR 4.9bn due to an increase in captive consumption. Management expects R&D to rise in FY25 to ~8-10% of sales.

### Financial Summary

Y/E March (INR mn)	FY23A	FY24A	FY25E	FY26E
Net Revenue	4,37,271	4,83,309	5,28,284	5,71,079
EBITDA	1,14,882	1,28,571	1,49,638	1,66,979
EBITDA Margin (%)	26.3	26.6	28.3	29.2
Net Profit	87,894	1,02,151	1,14,519	1,29,425
EPS (INR)	36.6	42.6	47.7	53.9
EPS % Chg YoY	160.3	13.2	21.7	13.0
P/E (x)	49.5	43.7	35.9	31.8
EV/EBITDA (x)	35.1	30.8	26.0	22.8
RoCE (%)	14.8	15.0	15.5	15.8
RoE (%)	16.9	17.1	17.0	17.1

### Abdulkader Puranwala

abdulkader.puranwala@icicisecurities.com  
+91 22 6807 7339

### Nisha Shetty

nisha.shetty@icicisecurities.com

### Market Data

Market Cap (INR)	4,115bn
Market Cap (USD)	49,142mn
Bloomberg Code	SUNP IN
Reuters Code	SUN.BO
52-week Range (INR)	1,746 /1,068
Free Float (%)	45.0
ADTV-3M (mn) (USD)	45.9

Price Performance (%)	3m	6m	12m
Absolute	14.2	21.8	50.0
Relative to Sensex	4.3	7.6	26.8

Earnings Revisions (%)	FY25E	FY26E
Revenue	0.0	0.0
EBITDA	2.0	1.3
EPS	5.7	5.0

### Previous Reports

23-05-2024: [Q4FY24 results review](#)

01-02-2024: [Q3FY24 results review](#)

## Valuation and risks

Sun's Q1 results were driven by solid traction in its India business. The company has grown at ~16% YoY in India, as compared to the market's growth of ~9%. Despite being the largest company in India, Sun has been able to increase its market share from 8.3% to 8.6% YoY in India through sales force addition (MR count increased from 9,707 in FY20 to 13,984 in FY24) and a steady number of new launches (160 brands launched in two years).

US growth had been a bit tepid due to seasonality impact in Levulan; however, with better traction in Ilumya (up 37.8% in FY24) and Winlevi we expect Sun's specialty biz to grow at a 18.7% CAGR over FY24-26E. Sales of gRevlimid were flat QoQ, indicating there is no improvement in market share of this product, unlike a few of its peers who have also launched this product in the US.

Remediation for Halol and Mohali is ongoing, though there are no critical filings pending from these sites. Strong sales from India and emerging markets coupled with better product mix has lifted gross margins by an impressive 200bps YoY to ~78.9% in Q1FY25. Marketing cost for launch of Nidlegy in Europe and Leqselvi in US is expected to increase when these products are launched in the near term; besides, it has six specialty assets across phases in clinical trial, which are also likely to increase its R&D spending. We envisage Sun spending ~7% of its revenues on R&D (CAGR of 12% over FY24-26E).

We raise our FY25E/26E EBITDA by 1-2% while earnings by 5-6% to factor in higher other income. We expect 8.7% revenue and 12.6% adj. PAT CAGRs over FY24-26E. We see EBITDA margin improving to 29.2% with improving revenue mix towards specialty. The stock currently trades at a pricey 35.9x FY25E and 31.8x FY26E earnings; and EV/EBITDA multiples of 26x FY25E and 22.8x FY26E, which curbs potential upside from its current levels. We retain our **HOLD** rating on the stock with a higher target price of INR 1,635 (earlier INR 1,463) based on 30x FY26E EPS (28x FY26E earlier).

**Key downside risks:** Higher-than-expected pricing pressures in the US; and regulatory hurdles.

**Key upside risks:** Faster ramp-up in specialty assets in US; and M&A.

## Q1FY25 conference call highlights

### India

- It launched six new products in Q1.
- Sun's market share has improved from 8.3% in FY24 to 8.6% in the Indian pharma market (IPM).
- The company witnessed growth across therapies. Increase in prescription volumes and new product launches have boosted growth in India.
- In India, Sun aims to grow in-line or slightly higher than IPM's growth rate.

### US generics

- US generic biz has grown, after excluding gRevlimid.
- Sales of gRevlimid were flat on a QoQ-basis. The product was an insignificant contributor in Q1, though is an important product for the US generic segment.
- It filed one ANDA and received approval for three ANDAs in Q1.

- There are no critical launches lined up from Halol and Mohali plants. Though there are a few products that await USFDA approval, which are filed from these sites.
- Remediation of the Halol plant is ongoing and the company will invite USFDA for a re-inspection once it has completed remediation.

### Global specialty

- Sequential drop in specialty sales is due to lower sales of Levulan, barring which other products have grown sequentially.
- A motion seeking a preliminary injunction has been filed in a US court to prevent the launch of Leqselvi (approved by USFDA on 25 Jul'24).
- The company incurred expenses related to Leqselvi in Q1FY25. Post launch, expenses are likely to increase further.
- 45.2% of Q1 R&D spending was towards its specialty business. Specialty R&D pipeline comprises of six products undergoing clinical studies.
- The company is working on improving realisation for Winlevi. On a small base, revenue has been growing sequentially.
- Sun does not have an established front-end to commercialise its own GLP-1 product in US/Europe; hence, is open for partnerships and out-licensing the product.
- Ilumya has headroom to grow in current indication. The product has a market share of 0.5% across the entire psoriasis market and 8% in IL-23 market.
- Sun has completed one arm of the study for psoriatic arthritis of Ilumya. The top-line data of phase-3 trial will be out in H2CY25.
- Ilumetri is being well-accepted in hospitals across China. Sales from this product will be lumpy on a quarterly basis.
- Delay in patient recruitments has led to shift in the time line for phase-2 trial of SCD-044 for atopic dermatitis indication.

### Other businesses

- RoW market growth was impacted due to price cuts in Japan.
- API sales had declined in Q1 due to increase in captive consumption for key products.

### Guidance

- Effective tax rate is expected to increase ahead.
- Maintained R&D guidance of 8–10% of sales for FY25E.

### Q1FY25 performance

- Improvement in gross margins was due to improvement in product mix.
- Higher R&D and SG&A cost led to surge in other expenses.
- Sun had net cash balance of USD 2.3bn at end of Q1FY25.

### Exhibit 1: Quarterly review

Particulars (INR mn)	Q1FY25	Q1FY24	YoY % Chg	Q4FY24	QoQ % Chg	FY24	FY23	YoY % Chg
<b>Net Sales</b>	<b>1,26,528</b>	<b>1,19,408</b>	<b>6.0</b>	<b>1,19,829</b>	<b>5.6</b>	<b>4,83,309</b>	<b>4,37,271</b>	<b>10.5</b>
Gross Profit	99,773	91,827	8.7	96,025	3.9	3,76,682	3,30,649	13.9
Gross margins(%)	78.9	76.9	200bps	80.1	-130bps	77.9	75.6	230bps
<b>EBITDA</b>	<b>36,076</b>	<b>33,318</b>	<b>8.3</b>	<b>30,352</b>	<b>18.9</b>	<b>1,28,571</b>	<b>1,14,882</b>	<b>11.9</b>
<b>EBITDA margins (%)</b>	<b>28.5</b>	<b>27.9</b>	<b>60bps</b>	<b>25.3</b>	<b>320bps</b>	<b>26.6</b>	<b>26.3</b>	<b>30bps</b>
Other income	5,326	2,044	160.5	6,059	(12.1)	13,542	6,345	113.4
PBIDT	41,402	35,362	17.1	36,411	13.7	1,42,113	1,21,227	17.2
Depreciation	6,551	6,513	0.6	6,504	0.7	25,566	25,294	1.1
Interest	615	809	(23.9)	736	(16.4)	2,385	1,720	38.6
Extra ordinary income/ (exp.)	-	(3,229)		(1,016)		(3,283)	(128)	
<b>PBT</b>	<b>34,235</b>	<b>24,812</b>	<b>38.0</b>	<b>28,155</b>	<b>21.6</b>	<b>1,10,879</b>	<b>94,084</b>	<b>17.9</b>
Tax	5,523	4,681	18.0	1,489	270.8	14,395	8,476	69.8
Minority Interest	249	(169)	(247.4)	42	498.3	337	394	(14.5)
Share of profit in JV	(107)	(74)		(79)		(384)	(479)	
<b>Reported PAT</b>	<b>28,356</b>	<b>20,226</b>	<b>40.2</b>	<b>26,546</b>	<b>6.8</b>	<b>95,764</b>	<b>84,736</b>	<b>13.0</b>
<b>Adjusted PAT</b>	<b>28,356</b>	<b>22,845</b>	<b>24.1</b>	<b>27,562</b>	<b>2.9</b>	<b>1,02,151</b>	<b>87,893</b>	<b>16.2</b>

Source: I-Sec research, Company data

### Exhibit 2: Business mix

Particulars (INR mn)	Q1FY25	Q1FY24	YoY % Chg	Q4FY24	QoQ % Chg	FY24	FY23	YoY % Chg
<b>Formulations</b>	<b>1,19,848</b>	<b>1,11,805</b>	<b>7.2</b>	<b>1,13,260</b>	<b>5.8</b>	<b>4,54,048</b>	<b>4,09,200</b>	<b>11.0</b>
India	41,445	35,604	16.4	37,078	11.8	1,48,893	1,36,031	9.5
US	38,894	38,709	0.5	39,544	(1.6)	1,53,493	1,35,353	13.4
US (USD mn)	466	471	(1.1)	476	(2.1)	1,854	1,684	10.1
Emerging Markets	23,695	21,452	10.5	20,348	16.5	86,195	78,977	9.1
RoW	15,814	16,041	(1.4)	16,290	(2.9)	65,468	58,839	11.3
<b>APIs &amp; Others</b>	<b>5,397</b>	<b>6,046</b>	<b>(10.7)</b>	<b>4,873</b>	<b>10.8</b>	<b>19,187</b>	<b>19,724</b>	<b>(2.7)</b>
<b>Other Op. Income</b>	<b>1,282</b>	<b>1,557</b>	<b>(17.6)</b>	<b>1,696</b>	<b>(24.4)</b>	<b>2,690</b>	<b>2,279</b>	<b>18.0</b>
<b>Total Sales</b>	<b>1,26,528</b>	<b>1,19,408</b>	<b>6.0</b>	<b>1,19,829</b>	<b>5.6</b>	<b>4,75,925</b>	<b>4,31,203</b>	<b>10.4</b>

Source: I-Sec research, Company data

### Exhibit 3: Key growth drivers of domestic business in Q1FY25

Brands (INR mn)	Q1FY25	Q1FY24	YoY (%)	Q4FY24	QoQ (%)	MAT MAR'24	MAT MAR'23	YoY (%)
Rosuvastatin	1,262	1,019	23.8	1,162	8.6	4,316	3,527	22.4
Levipil	1,051	965	8.9	997	5.4	4,038	3,617	11.6
Volini	815	864	-5.7	737	10.6	3,444	3,457	-0.4
Gemer	845	872	-3.1	805	5.0	3,343	3,143	5.1
Susten	801	768	4.2	748	7.0	2,921	2,775	5.3
Pantocid	773	700	10.4	707	9.3	2,871	2,620	9.6
Pantocid-D	709	647	9.5	663	6.8	2,649	2,453	8.0
Montek-Lc	464	488	-4.9	619	-25.1	2,434	2,300	5.8
Sompraz-D	644	538	19.8	608	5.9	2,292	1,916	19.6
Moxclav	504	427	18.1	611	-17.4	2,256	2,295	-1.7

Source: IQVIA

### Exhibit 4: Growth profile of key therapies in India

Therapies (INR mn)	Q1FY25	Q1FY24	YoY (%)	Q4FY24	QoQ (%)	MAT MAR'24	MAT MAR'23	YoY (%)
Neuro / CNS	7,877	7,168	9.9	7,377	6.8	29,200	26,497	10.2
Cardiac	7,645	7,039	8.6	7,229	5.8	28,494	25,976	9.7
Gastro Intestinal	5,992	5,403	10.9	5,413	10.7	21,937	19,866	10.4
Anti-Infectives	3,347	3,183	5.1	3,656	-8.5	14,632	14,187	3.1
Pain / Analgesics	3,556	3,132	13.5	3,156	12.7	12,897	11,656	10.6
Anti-Diabetic	3,475	3,052	13.9	3,174	9.5	12,437	11,181	11.2
Respiratory	1,845	1,813	1.7	2,324	-20.6	8,822	8,273	6.6
Derma	1,902	1,818	4.6	1,728	10.1	7,265	7,121	2.0
Vitamins/Minerals/Nutrients	1,890	1,758	7.5	1,709	10.6	7,048	6,824	3.3
Gynaec.	1,807	1,708	5.8	1,649	9.6	6,679	6,330	5.5


Source: IQVIA

### Exhibit 5: Sun's global specialty pipeline

Candidate	Indication	Current phase	Next milestone
deuruxolitinib	alopecia areata	Approved for alopecia areata in the US	Launch
Nidlegy <sup>TM</sup> (EU, ANZ rights with Sun)	melanoma and non-melanoma skin cancers	Filed with EMA (EU) for treatment of locally advanced, fully resectable melanoma in the neoadjuvant setting	Approval
Ilumya	psoriatic arthritis	Phase-3	Topline data during H2CY25
MM-II	pain in osteoarthritis	Phase-2 completed	Phase-3 to start in H1CY25
SCD-044	psoriasis atopoc dermatitis	Phase-2	Topline data by H1CY25 Topline data by H1CY25
GL0034	type-2 diabetes & obesity	Phase-1 completed	Phase-2 to start by H2CY24


Source: Company data, I-Sec research

### Exhibit 6: US generic business grew sequentially ex-Revlimid




Source: I-Sec research, Company data

### Exhibit 7: US revenue to touch USD 2.2bn by FY26E




Source: I-Sec research, Company data

### Exhibit 8: New product launches and better volumes across therapies boosted India growth




Source: I-Sec research, Company data

### Exhibit 9: Strong volumes and calibrated pricing to drive 9% CAGR growth in India over FY24-26E




Source: I-Sec research, Company data

**Exhibit 10: Strong performance in India and emerging markets aids growth**




Source: I-Sec research, Company data

**Exhibit 11: Revenue to grow 8.7% over FY24-26E**




Source: I-Sec research, Company data

**Exhibit 12: Gross margin expansion due to higher revenue from India branded business**




Source: I-Sec research, Company data

**Exhibit 13: Gross margin is expected to improve led by better product mix**




Source: I-Sec research, Company data

**Exhibit 14: Higher R&D and marketing costs curbed EBITDA growth**




Source: I-Sec research, Company data

**Exhibit 15: Higher specialty sales contribution to drive EBITDA margin going forward**




Source: I-Sec research, Company data

**Exhibit 16: R&D expense rose 16.8% YoY in Q1FY25**



Source: I-Sec research, Company data

**Exhibit 17: Specialty R&D to increase going forward**




Source: I-Sec research, Company data

**Exhibit 18: Shareholding pattern**

%	Dec'23	Mar'24	Jun'24
Promoters	54.5	54.5	54.5
Institutional investors	36.6	36.5	36.5
MFs and others	12.9	12.2	14.1
FIs/Banks	0.0	0.0	0.1
Insurance	5.0	5.1	4.9
FIIIs	18.6	19.3	17.4
Others	8.9	9.0	9.0

Source: Bloomberg

**Exhibit 19: Price chart**



Source: Bloomberg



## Financial Summary

### Exhibit 20: Profit & Loss

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
<b>Net Sales</b>	<b>4,37,271</b>	<b>4,83,309</b>	<b>5,28,284</b>	<b>5,71,079</b>
Operating Expenses	2,15,767	2,48,111	2,65,789	2,84,855
<b>EBITDA</b>	<b>1,14,882</b>	<b>1,28,571</b>	<b>1,49,638</b>	<b>1,66,979</b>
EBITDA Margin (%)	26.3	26.6	28.3	29.2
Depreciation & Amortization	25,294	25,566	26,440	27,934
EBIT	89,588	1,03,005	1,23,198	1,39,045
Interest expenditure	1,720	2,385	1,784	1,424
Other Non-operating Income	6,345	13,542	12,625	13,793
<b>Recurring PBT</b>	<b>94,213</b>	<b>1,14,162</b>	<b>1,34,039</b>	<b>1,51,414</b>
<b>Profit / (Loss) from Associates</b>	<b>(479)</b>	<b>(384)</b>	<b>(384)</b>	<b>(384)</b>
Less: Taxes	8,476	14,395	18,765	21,198
PAT	85,737	99,768	1,15,273	1,30,216
Less: Minority Interest	(394)	(337)	(370)	(407)
Extraordinaries (Net)	(1,715)	(4,943)	-	-
<b>Net Income (Reported)</b>	<b>83,150</b>	<b>94,104</b>	<b>1,14,519</b>	<b>1,29,425</b>
<b>Net Income (Adjusted)</b>	<b>87,894</b>	<b>1,02,151</b>	<b>1,14,519</b>	<b>1,29,425</b>

Source Company data, I-Sec research

### Exhibit 21: Balance sheet

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Total Current Assets	3,05,107	3,48,904	4,36,218	5,34,614
of which cash & cash eqv.	57,703	1,05,207	1,72,414	2,50,925
Total Current Liabilities & Provisions	1,35,810	1,40,144	1,51,228	1,62,018
<b>Net Current Assets</b>	<b>1,69,297</b>	<b>2,08,761</b>	<b>2,84,990</b>	<b>3,72,596</b>
Investments	1,48,243	1,50,258	1,50,258	1,50,258
Net Fixed Assets	1,03,904	1,01,923	96,233	89,049
ROU Assets	-	-	-	-
Capital Work-in-Progress	9,634	11,077	11,077	11,077
Total Intangible Assets	1,76,849	1,72,652	1,72,652	1,72,652
Other assets	5,434	5,919	5,919	5,919
Deferred Tax Assets	58,259	63,887	63,887	63,887
<b>Total Assets</b>	<b>6,71,626</b>	<b>7,14,485</b>	<b>7,85,026</b>	<b>8,65,448</b>
<b>Liabilities</b>				
<b>Borrowings</b>	<b>68,859</b>	<b>32,737</b>	<b>26,737</b>	<b>20,737</b>
<b>Deferred Tax Liability</b>	<b>317</b>	<b>1,551</b>	<b>1,551</b>	<b>1,551</b>
provisions	3,429	4,139	4,524	4,891
other Liabilities	5,866	4,999	4,999	4,999
Equity Share Capital	5,59,954	6,36,668	7,12,452	7,98,101
Reserves & Surplus	33,201	34,392	34,762	35,170
<b>Total Net Worth</b>	<b>5,93,155</b>	<b>6,71,060</b>	<b>7,47,215</b>	<b>8,33,271</b>
Minority Interest	-	-	-	-
<b>Total Liabilities</b>	<b>6,71,626</b>	<b>7,14,485</b>	<b>7,85,026</b>	<b>8,65,448</b>

Source Company data, I-Sec research

### Exhibit 22: Cashflow statement

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
<b>Operating Cashflow</b>	<b>49,593</b>	<b>1,21,350</b>	<b>1,34,475</b>	<b>1,50,461</b>
Working Capital Changes	(9,730)	12,014	(13,816)	(13,655)
Capital Commitments	(78,178)	(13,109)	(20,750)	(20,750)
<b>Free Cashflow</b>	<b>1,27,771</b>	<b>1,34,458</b>	<b>1,55,225</b>	<b>1,71,211</b>
<b>Other investing cashflow</b>	<b>(1,259)</b>	<b>6,207</b>	-	-
Cashflow from Investing Activities	(79,437)	(6,902)	(20,750)	(20,750)
Issue of Share Capital	-	-	-	-
Interest Cost	(1,720)	(2,385)	(1,784)	(1,424)
Inc (Dec) in Borrowings	-	-	-	-
Dividend paid	(25,197)	(28,982)	(38,734)	(43,776)
Others	64,130	(35,735)	(6,000)	(6,000)
Cash flow from Financing Activities	37,213	(67,102)	(46,518)	(51,200)
<b>Chg. in Cash &amp; Bank balance</b>	<b>7,369</b>	<b>47,346</b>	<b>67,207</b>	<b>78,511</b>
Closing cash & balance	57,703	1,05,049	1,72,414	2,50,925

Source Company data, I-Sec research

### Exhibit 23: Key ratios

(Year ending March)

	FY23A	FY24A	FY25E	FY26E
<b>Per Share Data (INR)</b>				
Reported EPS	34.7	39.2	47.7	53.9
Adjusted EPS (Diluted)	36.6	42.6	47.7	53.9
Cash EPS	47.2	53.2	58.8	65.6
Dividend per share (DPS)	11.5	13.5	16.1	18.2
Book Value per share (BV)	233.4	265.4	296.9	332.6
Dividend Payout (%)	33.2	34.4	33.8	33.8
<b>Growth (%)</b>				
Net Sales	13.1	10.5	9.3	8.1
EBITDA	10.5	11.9	16.4	11.6
EPS (INR)	160.3	13.2	21.7	13.0
<b>Valuation Ratios (x)</b>				
P/E	49.5	43.7	35.9	31.8
P/CEPS	36.4	32.2	29.2	26.2
P/BV	7.3	6.5	5.8	5.2
EV / EBITDA	35.1	30.8	26.0	22.8
P / Sales	9.4	8.5	7.8	7.2
Dividend Yield (%)	0.0	0.0	0.0	0.0
<b>Operating Ratios</b>				
Gross Profit Margins (%)	75.6	77.9	78.6	79.1
EBITDA Margins (%)	26.3	26.6	28.3	29.2
Effective Tax Rate (%)	9.2	12.8	14.0	14.0
Net Profit Margins (%)	20.1	21.1	21.7	22.7
NWC / Total Assets (%)	-	-	-	-
Net Debt / Equity (x)	(0.2)	(0.3)	(0.4)	(0.5)
Net Debt / EBITDA (x)	(1.2)	(1.7)	(2.0)	(2.3)
<b>Profitability Ratios</b>				
RoCE (%)	14.8	15.0	15.5	15.8
RoE (%)	16.9	17.1	17.0	17.1
RoC (%)	18.1	18.9	21.0	23.6
Fixed Asset Turnover (x)	4.2	4.7	5.3	6.2
Inventory Turnover Days	93	78	76	75
Receivables Days	101	89	89	88
Payables Days	50	45	43	42

Source Company data, I-Sec research



This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet\_babbar@icicisecuritiesinc.com, Rishi\_agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)  
**BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return**

#### ANALYST CERTIFICATION

I/We, Abdulkader Puranwala, MBA; Nisha Shetty, MBA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

#### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on [www.icicibank.com](http://www.icicibank.com).

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit [icidirect.com](http://icidirect.com) to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

---

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, E-mail Address : [complianceofficer@icicisecurities.com](mailto:complianceofficer@icicisecurities.com)

For any queries or grievances: [Mr. Bhavesh Soni](mailto:Mr. Bhavesh Soni) Email address: [headservicequality@icicidirect.com](mailto:headservicequality@icicidirect.com) Contact Number: 18601231122

---